leucine has been researched along with Chronic Hepatitis C in 195 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 119 (61.03) | 24.3611 |
| 2020's | 76 (38.97) | 2.80 |
| Authors | Studies |
|---|---|
| Flamm, SL; Martin, MT; Patel, S | 1 |
| Kakizaki, S; Kanayama, Y; Ohnishi, H; Okamoto, H; Sato, K; Suga, T; Tojima, H; Uehara, D; Uraoka, T; Yamazaki, Y; Yanagisawa, K | 1 |
| Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H | 1 |
| Feng, BL; Li, JM; Luo, JW; Naidoo, N; Wang, P; Wu, G; Xie, YX; Zhou, HJ | 1 |
| Hachisu, Y; Hatanaka, T; Hazama, Y; Kaburagi, T; Kakizaki, S; Kashiwabara, K; Murata, K; Naganuma, A; Nagashima, S; Nakano, S; Nishizawa, T; Okamoto, H; Saito, N; Takahashi, M; Tanaka, Y; Uraoka, T; Yamazaki, Y; Yoshida, S; Yoshinaga, T | 1 |
| Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L | 1 |
| Agarwal, K; Burroughs, M; Felizarta, F; Gane, E; Hassanein, T; Krishnan, P; Nevens, F; Overcash, JS; Poordad, F; Shaw, D; Topp, A; Waters, M; Yao, BB | 1 |
| Camus, G; Grant, PM; Gupta, N; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Mukabatsinda, C; Murangwa, A; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F | 1 |
| Christensen, PB; Dröse, S; Hansen, JF; Holm, DK; Madsen, LW; Røge, BT; Øvrehus, A | 1 |
| Abu-Freha, N; Abu-Hammad, T; Afawi, Z; Elhoashla, A; Elsana, F; Etzion, O; Mathew Jacob, B; Paz, S | 1 |
| Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD | 1 |
| Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ | 1 |
| Falade-Nwulia, O; Karimi-Sari, H; Lim, JK; Rezaee-Zavareh, MS | 1 |
| Cornberg, M; Hidde, D; Klinker, H; Lohmann, K; Lutz, T; Möller, H; Naumann, U; Simon, KG; Stoehr, A; Teuber, G | 1 |
| Chang, KC; Chang, TS; Chen, CH; Chen, WM; Chen, YH; Hsieh, YY; Hung, CH; Lu, CK; Lu, SN; Lu, YH; Tung, SY; Tung, WL; Yen, CW | 1 |
| Barclay, ST; Bradley-Stewart, A; Davis, C; Filipe, A; Fox, R; Gunson, R; MacLean, A; Ngan Chiu Bong, M; Peters, ES; Shah, R; Shepherd, SJ; Thomson, EC; Tong, L; van Vliet, VJE | 1 |
| Burroughs, M; Chayama, K; Eckert, D; Kato, K; Kumada, H; Lin, CW; Liu, W; Mensing, S; Oberoi, RK; Suleiman, AA | 1 |
| Cotter, TG; Jensen, DM | 1 |
| Aghemo, A; Asselah, T; Bräu, N; Brown, A; Chen, YJ; Conway, B; Grebely, J; Kleine, H; Lawitz, E; Lei, Y; Mensa, FJ; Negro, F; Pugatch, D; Puoti, M; Welzel, TM | 1 |
| Ankoma-Sey, V; Bondin, M; Dos Santos, AGP; Elkhashab, M; Fontana, RJ; Lens, S; McPherson, S; Porcalla, A; Trinh, R; Xue, Z; Zeuzem, S | 1 |
| Agarwal, K; Dore, GJ; Dos Santos, AGP; Feld, JJ; Gane, E; Hezode, C; Kho, D; Klein, M; Lacombe, K; Marks, P; Martinello, M; Matthews, GV; Mercade, GE; Muir, AJ; Müllhaupt, B; Petoumenos, K; Schultz, M; Tatsch, F; Thompson, A; Wedemeyer, H | 1 |
| Abergel, A; Aguilar, H; Brown, RS; Burroughs, M; Buti, M; Carrion, BR; Chuang, WL; Chulanov, V; Cohen, E; Felizarta, F; Horváth, G; Lin, CW; Lovell, SS; Mensa, FJ; Rodrigues, L; Rodriguez-Perez, F; Schnell, G; Trinh, R; Urbánek, P; Wang, S; Zha, J; Zuckerman, E | 1 |
| Chen, DS; Chen, PJ; Hsieh, SM; Hung, CC; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Sun, HY; Tseng, TC | 1 |
| Chayama, K; Gonzalez, YS; Kawaguchi, I; Kumada, H; Mitchell, D; Virabhak, S; Yuen, C | 1 |
| Aikata, H; Chayama, K; Hiramatsu, A; Imamura, M; Kawaoka, T; Morio, K; Murakami, E; Nakahara, T; Ohya, K; Tsuge, M; Yamauchi, M | 1 |
| Abunimeh, M; Aglitti, A; Bruchfeld, A; Flisiak, R; Jalundhwala, YJ; Kaskas, M; Lawitz, E; Mensa, FJ; Park, JY; Persico, M; Porcalla, A; Schnell, G; Sise, ME; Wörns, MA; Xue, Z; Zamor, PJ | 1 |
| Anderson, M; Caro, L; Chung, C; Fandozzi, C; Fraser, I; Gao, W; Howell, B; Mangin, E; Maxwell, J; Miltenburg, AMM; Popa, S; Railkar, R; Shire, NJ; Stoch, SA; Talal, AH; Van Dyck, K; Webber, AL; Wenning, L | 1 |
| Aschenbrenner, DS | 1 |
| Chung, RT; Holmes, JA | 1 |
| Ashraf, A; Kumar, R; Maitra, S; Singh, AD; Singh, N; Tyagi, P | 1 |
| Abe, H; Akahane, T; Asano, T; Atsukawa, M; Chuma, M; Fujioka, S; Fukunishi, S; Genda, T; Hiraoka, A; Iio, E; Ikeda, H; Ikegami, T; Ishikawa, T; Iwakiri, K; Kumada, T; Masaki, T; Michitaka, K; Mikami, S; Morishita, A; Moriya, A; Nakamuta, M; Nozaki, A; Ogawa, C; Okanoue, T; Okubo, H; Okubo, T; Shima, T; Shimada, N; Tachi, Y; Takaguchi, K; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsuji, K; Tsutsui, A; Uojima, H; Watanabe, T; Yamashita, N; Yasuda, S | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Lin, WT; Liu, CH; Liu, CJ; Peng, CY; Su, TH; Tseng, TC; Yang, SS | 1 |
| Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y | 1 |
| Kwo, PY; Kwong, AJ | 1 |
| Kumar, R; Singh, AD | 1 |
| Bacon, B; Curry, MP; Dylla, DE; Flamm, SL; Kort, J; Marx, SE; Strezewski, J; Tsai, N; Wick, N | 1 |
| Chang, TS; Chen, CH; Chen, MY; Chen, WM; Chiu, WN; Hu, JH; Hu, TH; Hung, CH; Lu, CK; Lu, SN; Tung, SY; Wei, KL | 1 |
| Bernhard, B; Stickel, F | 1 |
| Fargnoli, A; Gidea, CG; Jacobson, I; Kon, Z; Lewis, T; Lonze, B; Moazami, N; Pavone, J; Qian, Y; Rao, S; Reyentovich, A; Saraon, T; Smith, D | 1 |
| Abergel, A; Asselah, T; Fredrick, LM; Gane, E; George, C; Hung Le, M; Kowdley, KV; Kwo, PY; Lee, SS; Mensa, F; Nguyen, K; Nguyen, T; Pham, TT; Poordad, F; Schnell, G; Spearman, CW; Wong, F; Yao, BB | 1 |
| Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH | 1 |
| Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO | 1 |
| Caruntu, F; Cohen, S; de Ledinghen, V; Dillon, JF; Dylla, DE; Fredrick, LM; Gschwantler, M; Gutierrez, JA; Muir, AJ; Nevens, F; Pires Dos Santos, AG; Puoti, M; Rodrigues, L; Sigal, S; Slim, J; Zuckerman, E | 1 |
| Alami, NN; Asatryan, A; Burroughs, M; Fredrick, LM; Heo, J; Hou, J; Jia, J; Kalluri, HV; Kim, YJ; Krishnan, P; Lim, SG; Liu, W; Lu, W; Mobashery, N; Tripathi, R; Wang, G; Wei, L; Xie, Q; Xie, W; Zhang, M | 1 |
| Barclay, ST; Belperio, PS; Bondin, M; Flamm, S; Lampertico, P; Lohmann, K; Marra, F; Marx, S; Mauss, S; Persico, M; Wedemeyer, H; Zhang, Z | 1 |
| Chen, YY; Chou, KC; Hsu, YC; Huang, SP; Liu, IL; Su, PY; Wu, SS; Yang, CW; Yen, HH; Zeng, YH | 1 |
| Rodriguez-Reyes, M; Ruiz-Boy, S; Sotoca-Momblona, JM | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Cho, M; Heo, J; Hong, YM; Kim, DU; Kim, GH; Kim, HH; Park, SG; Park, YJ; Song, GA; Woo, HY; Yoon, KT | 1 |
| Chen, CH; Hsu, CS; Hsu, YC; Hui, YT; Kan, YM; Li, MKK; Liu, CH; Liu, KSH; Tsai, MC; Wong, GLH; Yap, DYH; Yu, ML; Yuen, MF | 1 |
| Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A | 1 |
| Cornberg, M; Deterding, K; Jung, MC; Klinker, H; Manns, MP; Sarrazin, C; Schulze Zur Wiesch, J; Serfert, Y; Simon, KG; Stoehr, A; Teuber, G; Vermehren, J; Wedemeyer, H; Zeuzem, S | 1 |
| Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S | 1 |
| Jiang, X; Xu, Y; Zhang, Y; Zhao, Y | 1 |
| Dronamraju, D; Kwo, P | 1 |
| Hernandez, C; Hezode, C; Mangia, A; Turnes, J | 1 |
| Singh, AD | 1 |
| Berak, H; Białkowska-Warzecha, J; Buczyńska, I; Citko, J; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Sobala-Szczygieł, B; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D; Łapiński, TW | 1 |
| Crehuá Gaudiza, E; Quintero García, D; Sebastián Cuevas, FJ | 1 |
| Biliotti, E; Cruciata, A; Mezzaroma, I; Milito, C; Rivano Capparuccia, M; Spaziante, M; Taliani, G; Volpicelli, L | 1 |
| Chen, HW; Hsieh, CB; Hsieh, TY; Lin, JC | 1 |
| Clerc, O; Magenta, L; Müllhaupt, B; Negro, F; Ruckstuhl, L; Semela, D; Semmo, N; Torgler, R | 1 |
| Buonomo, AR; Cattaneo, L; Coppola, C; Coppola, N; De Pascalis, S; Gentile, I; Martini, S; Mercinelli, S; Messina, V; Nerilli, M; Pinchera, B; Scotto, R; Staiano, L; Stanzione, M; Stornaiuolo, G | 1 |
| Erren, P; König, B; Lohmann, K; Mauss, S; Naumann, U; Rieke, A; Stoehr, A; Wedemeyer, H; Zimmermann, T | 1 |
| Hara, T; Iwai, N; Kagawa, K; Komaki, T; Nagata, A; Ohara, T; Oka, K; Okuda, T; Sakagami, J; Sakai, H; Taniguchi, M; Tsuji, T | 1 |
| Booth, J; Borgia, SM; Conway, B; Cooper, C; Feld, JJ; Lee, S; Lilly, LB; Morales, H; Onofrio, FQ; Ramji, A; Sattar, I; Vachon, ML; Wong, A | 1 |
| Buti, M; Campos, C; Cañizares, A; Carrión, JA; Castro-Iglesias, A; Costa, JG; Esteban, JI; Garcia-Cehic, D; Gregori, J; Macenlle, R; Pamplona, J; Quer, J; Rando, A; Rodriguez-Frias, F; Tabernero, D | 1 |
| Berg, T; Bondin, M; Cornberg, M; Klinker, H; Koenig, B; Lohmann, K; Naumann, U; Rössle, M; Zeuzem, S | 1 |
| Bourlière, M; Meszaros, M; Ouzan, D; Pageaux, GP; Tran, A; Truchi, R | 1 |
| Bondin, M; Brown, A; Burroughs, M; Chayama, K; Dylla, DE; Emmett, A; Feld, JJ; Forns, X; Gordon, SC; Heo, J; Hou, J; Jacobson, IM; Lampertico, P; Marcinak, J; Pol, S; Tatsch, F; Zhang, Z | 1 |
| Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S | 1 |
| Adachi, T; Akashi, H; Akutsu, N; Ban, T; Hirano, T; Ishigami, K; Isshiki, H; Kaneto, H; Matsui, T; Nakachi, K; Nakahara, S; Nakase, H; Numata, Y; Sasaki, S; Takagi, H; Tanaka, K; Tsujisaki, M; Wagatsuma, K; Yamamoto, I; Yamaoka, S; Yawata, A; Yonezawa, K | 1 |
| Alami, NN; Asatryan, A; Bae, SH; Cho, M; Crown, ED; Fredrick, LM; Han, KH; Heo, J; Jeong, SH; Kim, DH; Kim, JH; Kim, YJ; Lee, JW; Lee, YJ; Lim, YS; Paik, SW; Yoon, KT | 1 |
| Andrade, RJ; Calleja, JL; Calvo, M; Delgado, MB; Frias, YN; Gálvez-Fernández, RM; Gómez, J; López, MA; Manzano, ML; Molina, E; Olveira, A; París, S; Rincón, D; Rosales, JM; Salmerón, FJ; Santos de Lamadrid, R; Turnes, J; Vallejo-Senra, N | 1 |
| Bukh, J; Christensen, PB; Fahnøe, U; Madsen, LW; Pedersen, MS; Øvrehus, A | 1 |
| Ichijo, T; Joshita, S; Kawakami, F; Kobayashi, H; Nakazawa, H; Sugiura, A; Umemura, T; Wakabayashi, SI; Yamashita, Y; Yamazaki, T | 1 |
| Ahmed, S; Ajaimy, M; Campbell, A; Graham, JA; Jorde, UP; Nnani, DU; Patel, SR; Saeed, O | 1 |
| Barclay, ST; Burroughs, M; Calleja, JL; de Ledinghen, V; Dylla, DE; Gane, E; Gutierrez, JA; Rizzardini, G; Shiffman, ML; Xue, Z | 1 |
| Agarwal, K; Asselah, T; Berg, T; Bhandari, BR; Borgia, SM; Brainard, DM; Bräu, N; Davis, M; Dore, GJ; Dvory-Sobol, H; Feld, JJ; Foster, GR; Gane, EJ; Hyland, RH; Jacobson, IM; Lawitz, E; McHutchison, JG; Nahass, RG; Pearlman, B; Roberts, SK; Ruane, PJ; Shafran, SD; Stamm, LM; Stedman, CAM; Subramanian, GM; Svarovskaia, E; Thompson, AJ; Willems, BE; Workowski, KA; Zhu, Y | 1 |
| Agarwal, K; Aguilar, H; Asatryan, A; Dore, GJ; Felizarta, F; Gane, E; Gordon, SC; Hassanein, T; Kort, J; Kwo, PY; Lin, CW; Liu, R; Lovell, SS; Maliakkal, B; Mensa, FJ; Muir, AJ; Ng, TI; Overcash, JS; Poordad, F; Sulkowski, MS; Wang, S; Wyles, DL | 1 |
| Jacobson, IM; Voaklander, R | 1 |
| Asatryan, A; Campbell, A; Ding, B; Dutta, S; Kort, J; Lin, CW; Liu, W; Podsadecki, T; Wang, T; Zadeikis, N | 1 |
| Asatryan, A; Geoffroy, P; Kort, J; Kosloski, MP; Liu, W; Zhao, W | 1 |
| Alves, K; Atarashi, T; Atsukawa, M; Burroughs, M; Chayama, K; Fu, B; Kato, K; Kumada, H; Naganuma, A; Nakamuta, M; Notsumata, K; Oberoi, RK; Osaki, Y; Pilot-Matias, TJ; Pugatch, D; Redman, R; Saito, S; Sato, K; Suzuki, F; Takaguchi, K; Toyoda, H; Watanabe, T | 1 |
| Agarwal, K; Alric, L; Felizarta, F; Hassanein, T; Kort, J; Krishnan, P; Kwo, PY; Lee, SS; Lin, CW; Liu, R; Lovell, SS; Maliakkal, B; Mensa, FJ; Pilot-Matias, T; Poordad, F; Wang, S; Weilert, F; Wyles, D | 1 |
| Lamb, YN | 1 |
| Alves, K; Atarashi, T; Burroughs, M; Chayama, K; Eguchi, Y; Karino, Y; Kato, K; Kawakami, Y; Krishnan, P; Kumada, H; Naganuma, A; Oberoi, RK; Pilot-Matias, TJ; Pugatch, DL; Redman, R; Sato, K; Seike, M; Suzuki, F; Takei, Y; Watanabe, T; Xie, W; Yoshiji, H | 1 |
| Agarwal, K; Aguilar, H; Asselah, T; Calinas, F; Colombo, M; de Ledinghen, V; Elkhashab, M; Hassanein, T; Hezode, C; Horsmans, Y; Kort, J; Kowdley, KV; Krishnan, P; Lin, CW; Liu, R; Mantry, PS; Marinho, RT; Mensa, FJ; Nevens, F; Ng, TI; Wang, S; Zadeikis, N | 1 |
| Bräu, N; Brown, A; Collins, C; Colombo, M; Gane, E; Kosloski, M; Lawitz, E; Lei, Y; Leroy, V; Mensa, FJ; Moreno, C; Nelson, DR; Papatheodoridis, G; Persico, M; Pol, S; Pugatch, D; Yoshida, EM | 1 |
| Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K | 1 |
| Kottilil, S; O'Brien, TR; Pfeiffer, RM | 1 |
| Asatryan, A; Bernstein, DE; Buti, M; Felizarta, F; Fried, MW; Gallant, J; Gordon, SC; Hézode, C; Kopecky-Bromberg, S; Kort, J; Krishnan, P; Lei, Y; Lin, CW; Mensa, FJ; Ng, TI; Pianko, S; Pol, S; Poordad, F; Reindollar, RW; Shaw, D | 1 |
| Bourliere, M; Cooper, C; Flamm, S; Gordon, S; Hunt, S; Jacobson, I; Kowdley, K; Mann, MP; Reddy, KR; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
| Beyer, J; Burroughs, M; Chayama, K; Collins, C; Dekhtyar, T; Fu, B; Irvin, M; Krishnan, P; Kumada, H; Pilot-Matias, T; Redman, R; Reisch, T; Schnell, G; Tripathi, R; Xie, W | 1 |
| Asselah, T; Foster, GR; Gane, EJ; Henry, L; Jacobson, IM; Lawitz, E; Pearlman, B; Racila, A; Roberts, SK; Stepanova, M; Thompson, AJ; Welzel, TM; Willems, BE; Younossi, I; Younossi, ZM | 1 |
| Hubbard, H; Lawitz, E | 1 |
| Younossi, ZM | 1 |
| Danta, M; Sanagapalli, S | 1 |
| Asatryan, A; Asselah, T; Bourlière, M; Bruck, R; Chuang, WL; Dore, GJ; Feld, JJ; Felizarta, F; Flamm, S; Flisiak, R; Foster, GR; Fu, B; Fuster, F; Gane, E; Kaita, K; Kort, J; Kwo, P; Lin, CW; Liu, R; Mensa, FJ; Ng, TI; Paik, SW; Pilot-Matias, T; Pol, S; Poordad, F; Puoti, M; Roberts, SK; Ruane, PJ; Sepulveda-Arzola, G; Soto-Malave, R; Stedman, CA; Tam, E; Trinh, R; Vargas, HE; Vierling, J; Wang, S; Wedemeyer, H; Zeuzem, S | 1 |
| Debes, JD; Singh, D | 1 |
| Deeks, ED; Heo, YA | 1 |
| Chang, TT; Dufour, JF; Foster, GR; Gane, E; Gordon, SC; Hezode, C; Lee, SS; Lovell, S; Marinho, R; Mensa, FJ; Moreno, C; Mutimer, D; Pilot-Matias, T; Pol, S; Puoti, M; Strasser, SI; Thuluvath, PJ; Wang, S; Zhang, Z | 1 |
| Cory, TJ; Gong, Y; Kodidela, S; Kumar, S; Mu, Y | 1 |
| Agarwal, K; Angus, P; Brown, RS; Dumas, EO; Forns, X; Gane, E; Gulati, A; Hu, YB; Kao, JH; Krishnan, P; Kwo, PY; Liu, W; Mantry, PS; Mutimer, D; Porcalla, A; Reau, N; Reddy, KR; Rhee, S; Samanta, S; Shulman, NS; Tran, TT; Trinh, R | 1 |
| Abutaleb, A; Kottilil, S; Wilson, E | 1 |
| Waked, I | 1 |
| Bourlière, M; Brainard, DM; Curry, MP; Dvory-Sobol, H; Gordon, SC; Hyland, RH; Landis, CS; Manns, MP; McHutchison, JG; Ravendhran, N; Reddy, KR; Schiff, ER; Sepe, TE; Serfaty, L; Stamm, LM; Subramanian, GM; Thompson, AJ; Tran, TT; Zhang, J | 1 |
| Bourliere, M; Gordon, SC; Manns, MP; Racila, A; Reddy, R; Schiff, E; Stepanova, M; Tran, T; Younossi, I; Younossi, ZM | 1 |
| Beyer, J; Collins, C; Dekhtyar, T; Irvin, M; Krishnan, P; Larsen, L; Mensa, FJ; Ng, TI; Pilot-Matias, T; Reisch, T; Schnell, G; Tripathi, R; Xie, W | 1 |
| Nehra, V; Rizza, SA; Temesgen, Z | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Bourliere, M; Brainard, DM; Camus, G; Cooper, CL; Doehle, BP; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Hyland, RH; Kowdley, KV; Manns, MP; Martin, R; Mo, H; Reddy, KR; Roberts, SK; Sarrazin, C; Stamm, LM; Svarovskia, E; Zeuzem, S | 1 |
| Asatryan, A; Beyer, J; Campbell, A; Collins, C; Dekhtyar, T; Irvin, M; Kort, J; Krishnan, P; Lawitz, EJ; Lovell, S; Lu, L; Mensa, F; Ng, TI; Pilot-Matias, T; Reisch, T; Schnell, G; Tripathi, R; Yao, B | 1 |
| Beyer, J; Collins, C; Dekhtyar, T; Irvin, M; Krishnan, P; Lu, L; Ng, TI; Pilot-Matias, T; Reisch, T; Schnell, G; Tripathi, R; Xie, W | 1 |
| Hinds, AE; Pearlman, BL | 1 |
| Fabrizi, F; Messa, P | 1 |
| Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Hiramatsu, A; Imamura, M; Kawaoka, T; Miki, D; Morio, K; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| Erlich, DR; Grover, A | 1 |
| Abergel, A; Asselah, T; Gane, E; Lee, SS; Lim, SG; Mahomed, A; Mensa, FJ; Nguyen, K; Nguyen, T; Porcalla, A; Sasadeusz, J; Schnell, G; Wong, F; Yao, BB; Zadeikis, N; Zhang, Z | 1 |
| Agarwal, K; Asatryan, A; Flamm, S; Gane, E; Heo, J; Horsmans, Y; Kopecky-Bromberg, S; Krishnan, P; Kwo, PY; Lovell, SS; Mensa, FJ; Mutimer, D; Ng, TI; Rockstroh, J; Ruane, PJ; Ryder, SD; Trinh, R; Villa, E; Wang, S; Weiland, O; Welzel, TM; Wyles, DL; Xue, Z | 1 |
| Caroleo, B; Caroleo, MC; Cimellaro, A; Colangelo, L; De Sarro, G; Di Mizio, G; Gallelli, L; Perticone, M | 1 |
| Baba, M; Izumi, T; Kawagishi, N; Kimura, M; Maehara, O; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
| Bondin, M; Cacoub, P; Fabrizi, F; Negro, F | 1 |
| Cenderello, G; Di Biagio, A; Taramasso, L | 1 |
| Liu, W; Lovell, S; Mensa, FJ; Pilot-Matias, T | 1 |
| Aghemo, A; Lleo, A; Plaz Torres, MC | 1 |
| Aguilar, H; Asatryan, A; Asselah, T; Baumgarten, A; Conway, B; Dore, GJ; Foster, GR; Grebely, J; Gschwantler, M; Hu, Y; Jackson, D; Mensa, FJ; Sherman, KE; Tomasiewicz, K; Wang, S | 1 |
| Chuang, WL; Crawford, DHG; Dokmeci, AK; Hamid, SS; Ibrahim, A; Jindal, A; Kanda, T; Kao, JH; Kumar, M; Lau, GKK; Lesmana, CRA; McCaughan, GW; Moriyama, M; Omata, M; Sarin, SK; Sharma, BC; Sollano, J; Wasim, J; Wei, L; Yokosuka, O; Yu, ML | 1 |
| Baba, M; Kawagishi, N; Kimura, M; Maehara, O; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
| Asatryan, A; Asselah, T; Foster, GR; Kopecky-Bromberg, S; Lei, Y; Mensa, FJ; Trinh, R; Zadeikis, N | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H | 1 |
| Brainard, DM; Dvory-Sobol, H; Gane, EJ; Hyland, RH; Nyberg, L; Ruane, P; Shafran, S; Shao, J; Stamm, LM; Strasser, SI; Tran, T | 1 |
| Althoff, CE; Bergfeld, L; Brakemeier, S; Budde, K; Duerr, M; Eckardt, KU; Glander, P; Halleck, F; Lehner, LJ; Marticorena Garcia, SR; Sack, I; Schrezenmeier, EV | 1 |
| Camus, G; Dvory-Sobol, H; Han, B; Hsieh, D; Lu, J; Martin, R; Mo, H; Parhy, B; Svarovskaia, ES | 1 |
| Abe, H; Aizawa, Y; Akahane, T; Atsukawa, M; Fukunishi, S; Genda, T; Hotta, N; Ikegami, T; Iwakiri, K; Kondo, C; Kumada, T; Michitaka, K; Nakamuta, M; Nozaki, A; Ogawa, C; Shima, T; Shimada, N; Tachi, Y; Takaguchi, K; Tanaka, Y; Toyoda, H; Tsubota, A; Tsuji, K; Uojima, H; Watanabe, T | 1 |
| Kiser, JJ | 1 |
| Asatryan, A; Elkhashab, M; Gane, E; Greenbloom, S; Lin, CW; Liu, W; Mensa, FJ; Mulkay, JP; Nguyen, T; Pilot-Matias, T; Poordad, F; Porcalla, A; Setze, C; Stedman, C; Tran, A; Valdes, J; Wang, S; Wörns, MA; Yu, Y; Zadeikis, N | 1 |
| Bukh, J; Dietz, J; Fahnøe, U; Filskov, J; Fourati, S; Ghanem, L; Gottwein, JM; Humes, D; Jensen, SB; Krarup, H; Pawlotsky, JM; Pedersen, MS; Pham, LV; Pihl, AF; Ramirez, S; Sarrazin, C; Schønning, K; Serre, SBN; Sølund, CS; Tang, Q; Weis, N | 1 |
| Back, D; Belperio, P; Bondin, M; Crown, E; Marra, F; Mensa, FJ; Negro, F; Park, C; Pinsky, B; Talal, AH; Zhang, Z | 1 |
| Hinds, A; Pearlman, B; Perrys, M | 1 |
| Koike, K; Tanaka, Y; Tateishi, R | 1 |
| Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E | 1 |
| Aglitti, A; Brancaccio, G; Caroleo, B; Claar, E; Coppola, C; Coppola, N; Cozzolongo, R; Di Costanzo, GG; Federico, A; Fontanella, L; Gatti, P; Gentile, I; Longo, A; Masarone, M; Messina, V; Milella, M; Morisco, F; Persico, M; Pierri, P; Rosato, V; Serviddio, G; Sogari, F; Surace, LA; Termite, AP; Terrenato, I; Tundo, P | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kasuya, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sano, T; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Cooke, G; Fawsitt, CG; Vickerman, P; Welton, NJ | 1 |
| Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J | 1 |
| Chen, CC; Chen, CH; Chen, DS; Chiu, MC; Fang, YJ; Hsu, SJ; Kao, JH; Kuo, CC; Lee, JY; Yang, TH; Yu, JJ | 1 |
| Fukuchi, T; Kakizaki, S; Naganuma, A; Namikawa, M; Ohnishi, H; Okamoto, H; Sato, K; Uraoka, T | 1 |
| An, D; Barnard, RJ; Bhanja, S; Gane, EJ; Gress, J; Hwang, P; Lawitz, E; Mobashery, N; Rodriguez-Torres, M; Serfaty, L; Stoehr, A | 1 |
| Boonstra, A; de Bruijne, J; de Knegt, RJ; Hotho, DM; Janssen, HL; Reesink, HW; Spaan, M; Treitel, MA | 1 |
| Angus, P; Arasteh, K; Asselah, T; Böcher, WO; Bronowicki, JP; Gane, E; Heim, M; Kukolj, G; Larrey, D; Lohse, AW; Mensa, FJ; Müllhaupt, B; Nehmiz, G; Pol, S; Roberts, S; Schuchmann, M; Stern, JO; Zarski, JP; Zeuzem, S; Zoulim, F | 1 |
| Barnard, RJ; Cheney, CA; Dinubile, MJ; Graham, DJ; Hazuda, DJ; Himmelberger, AL; Hwang, PM; McHale, CM; Mobashery, N; Newhard, W; Nickle, D; Reeves, JD; Rivera, AA; Strizki, J | 1 |
| Asselah, T; Böcher, WO; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Kukolj, G; Lohse, AW; Mensa, FJ; Müllhaupt, B; Roberts, SK; Schuchmann, M; Soriano, V; Stern, JO; Vinisko, R; Zeuzem, S | 1 |
| Kuboki, M; Nishiguchi, S; Omata, M; Sakai, Y; Sakamoto, W; Steinmann, G; Tsuda, Y; Tsunematsu, S; Urano, Y | 1 |
| Barnard, RJ; Bhanja, S; Bourque, M; DiNubile, MJ; Gane, EJ; Hwang, PM; Lawitz, E; Mobashery, N; Rodriguez-Torres, M; Serfaty, L; Stoehr, A; Strizki, J; Zhou, A | 1 |
| Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ | 1 |
| Berger, KL; Böcher, WO; Cartier, M; Datsenko, Y; Kukolj, G; Marquis, M; Massariol, MJ; Scherer, J; Steinmann, G; Stern, JO; Triki, I | 1 |
| Laufer, NL; Rockstroh, JK | 1 |
| Benhamou, Y; Shiffman, ML | 1 |
| Shiffman, ML | 1 |
| Agarwal, K; Austin, A; Barclay, ST; Brown, A; Dillon, JF; Dundas, P; Dusheiko, GM; Foster, GR; Fox, R; Hayes, PC; Leen, C; Miller, MH; Millson, C; Ryder, SD; Tait, J; Ustianowski, A | 1 |
| Böcher, WO; Hennecke, N; Kayser, A; Kukolj, G; Lohmann, V; Martin, B; Neumann-Haefelin, C; Thimme, R | 1 |
| Hayashi, N; Izumi, N; Mobashery, N | 1 |
| Böcher, W; Buti, M; Buynak, RJ; Dufour, JF; Gallivan, JP; Mantry, P; Mensa, FJ; Soriano, V; Stern, JO; Taunk, J; Vinisko, R; Zeuzem, S | 1 |
| Angus, P; Asselah, T; Böcher, W; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Manns, M; Mensa, FJ; Müllhaupt, B; Roberts, S; Sabo, JP; Schuchmann, M; Soriano, V; Stern, JO; Stickel, F; Voss, F; Zeuzem, S | 1 |
| Agarwal, K; Asselah, T; Bourlière, M; Calinas, F; Crespo, J; Datsenko, Y; Dufour, JF; Ferenci, P; Forton, D; Foster, GR; Garcia, M; Kukolj, G; Maevskaya, M; Morano, LE; Moreno, C; Nishiguchi, S; Omata, M; Ouzan, D; Quinson, AM; Sarrazin, C; Scherer, J; Schuchmann, M; Stern, JO; Zehnter, E; Zeuzem, S | 1 |
| Arastéh, K; Bhagani, S; Dieterich, D; Guardiola, JM; Ingiliz, P; Jain, MK; Kort, J; Laguno, M; Manero, M; Nelson, M; Rockstroh, JK; Soriano, V; Stern, JO; Tural, C; Vinisko, R | 1 |
| Anderson, M; Caro, L; Cerra, M; Du, L; Manns, MP; Nachbar, RB; Panorchan, P; Potthoff, A; Talal, AH; Wagner, J; Wright, DH | 1 |
| Ambrosioni, J; Aouri, M; Böni, J; Cavassini, M; Decosterd, L; Fehr, J; Furrer, H; Günthard, HF; Haubitz, S; Kovari, H; Ledergerber, B; Metzner, KJ; Rauch, A; Schaerer, V; Schmid, P; Stoeckle, M | 1 |
| Berger, KL; Kukolj, G; Quinson, AM; Ranga, M; Scherer, J; Sha, N; Stern, JO | 1 |
| Hayashi, N; Howe, AY; Kumada, H; Ludmerer, SW; Mobashery, N; Nakamuta, M; Takase, A; Takehara, T | 1 |
| Asselah, T; Bourlière, M; Dufour, JF; Ferenci, P; Forton, D; Foster, GR; García-Samaniego, J; Maevskaya, M; Mantry, P; Oliveira, C; Quinson, AM; Sha, N; Stern, JO; Warner, N; Wright, D; Wright, M; Yoshida, EM | 1 |
| Asatryan, A; Box, TD; Campbell, A; Freilich, BL; Kort, J; Lawitz, EJ; Lin, CW; Liu, W; Lovell, S; Ng, TI; O'Riordan, WD; Overcash, JS; Yao, B | 1 |
| Takehara, T | 1 |
| Chayama, K; Fujimoto, G; Howe, AY; Karino, Y; Kumada, H; Ludmerer, SW; Mobashery, N; Mochida, S; Nakamura, K; Suzuki, F | 1 |
| An, D; Brainard, DM; Di Bisceglie, AM; Dvory-Sobol, H; Freilich, B; Glass, S; Hassman, D; Hill, J; Kim, S; Kirby, BJ; Krefetz, D; Lawitz, E; Marbury, T; Rodriguez-Torres, M; Smith, W; Stamm, LM; Taylor, JG; Yang, JC | 1 |
| Imaizumi, N; Kashiwagi, T; Kashiwamura, S; Kishida, Y; Tanimura, H | 1 |
| Angus, P; Böcher, W; Buti, M; Buynak, RJ; Dufour, JF; Kadus, W; Mantry, P; Mensa, FJ; Pockros, PJ; Soriano, V; Stern, JO; Vinisko, R; Wright, D; Zeuzem, S | 1 |
| Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z | 1 |
| Beavers, K; Bernstein, D; Brainard, DM; Chung, RT; Davis, M; Dvory-Sobol, H; Etzkorn, K; Everson, G; Gane, EJ; Gordon, SC; Khalid, O; Kowdley, KV; Kwo, PY; Lu, S; McHutchison, JG; Nguyen, MH; Poulos, JE; Pound, D; Rodriguez-Torres, M; Stamm, LM; Stedman, CA; Tong, M; Tsai, N; Yang, JC | 1 |
| Berger, KL; Côté-Martin, A; Kukolj, G; Marquis, M; Mensa, FJ; Nelson, DR; Sarrazin, C; Scherer, J; Sha, N; Stern, JO; Vinisko, R | 1 |
| Bai, X; Calleja, JL; Forns, X; Garcia-Samaniego, J; Kaste, R; Manns, M; Sarrazin, C; Stern, JO; Wu, J | 1 |
| Asatryan, A; Bernstein, DE; Felizarta, F; Flamm, SL; Fried, MW; Gordon, SC; Kort, J; Landis, CS; Lin, CW; Liu, R; Lovell, SS; Mensa, FJ; Ng, TI; Poordad, F; Reindollar, RW; Sulkowski, MS | 1 |
| Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y | 1 |
| Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, EA; Janssen, HL; Li, J; Molenkamp, R; Reesink, HW; Schinkel, J; Tong, X; Treitel, MA; van Lier, JJ; van Vliet, AA; Weegink, CJ | 1 |
| Carroll, SS; Davies, ME; Graham, D; Handt, L; Hazuda, D; Koeplinger, K; Liverton, N; Ludmerer, SW; MacCoss, M; Olsen, DB; Zhang, NR | 1 |
| Kaneoka, Y; Kumada, T; Maeda, A; Toyoda, H | 1 |
| Khungar, V; Poordad, F | 1 |
| Angus, P; Arasteh, K; Asselah, T; Boecher, WO; Bronowicki, JP; Gane, E; Haefner, C; Heim, M; Kukolj, G; Larrey, D; Lohse, A; Müllhaupt, B; Nehmiz, G; Pol, S; Roberts, S; Schuchmann, M; Stern, JO; Zarski, JP; Zeuzem, S; Zoulim, F | 1 |
| Bousquet, C; Dansereau, N; Dô, F; Kukolj, G; Lagacé, L; Llinas-Brunet, M; Marquis, M; Massariol, MJ; Maurice, R; Spickler, C; Thibeault, D; Triki, I; White, PW; Zhao, S | 1 |
| Lok, AS; Sharma, P | 1 |
| Barnard, RJ; Caro, L; Gane, E; Hwang, PM; Lee, AW; Manns, MP; Marcellin, P; Rodriguez-Torres, M; Stoehr, A; Wiedmann, RT; Yeh, CT | 1 |
| Asselah, T; Bessone, F; Böcher, WO; Datsenko, Y; Fainboim, H; Ferenci, P; Heo, J; Kukolj, G; Lalezari, J; Leggett, B; Mauss, S; Nehmiz, G; Scherer, J; Steinmann, GG; Stern, JO; Sulkowski, MS | 1 |
29 review(s) available for leucine and Chronic Hepatitis C
| Article | Year |
|---|---|
Chronic hepatitis C: Diagnosis and treatment made easy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis | 2022 |
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Design; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Microbial Sensitivity Tests; Molecular Conformation; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants | 2020 |
Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Non-Randomized Controlled Trials as Topic; Proline; Pyrrolidines; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins | 2020 |
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: case report and literature review.
Topics: Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Republic of Korea; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature.
Topics: Aged; Aminoisobutyric Acids; Antibodies, Monoclonal; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Multiple Myeloma; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Glecaprevir/Pibrentasvir: First Global Approval.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Approval; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2017 |
Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carrier Proteins; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Drug Resistance, Viral; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Costs; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides | 2018 |
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2018 |
Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Managing hepatitis C therapy failures and chronic kidney disease.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Cardiovascular Diseases; Cyclopropanes; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sulfonamides; Treatment Failure | 2018 |
Expert opinion on the management of renal manifestations of chronic HCV infection.
Topics: 2-Naphthylamine; Amides; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Disease Management; Drug Therapy, Combination; Expert Testimony; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Practice Guidelines as Topic; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Risk Factors; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Treatment of hepatitis C virus genotype 4 in the DAA era.
Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Fibrosis; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Sulfonamides; Treatment Outcome | 2019 |
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
Topics: 2-Naphthylamine; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Denmark; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Prognosis; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Uracil; Valine | 2019 |
Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Administration Routes; Drug Therapy, Combination; Female; Gastrostomy; Hepatitis C, Chronic; Humans; Intubation, Gastrointestinal; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.
Topics: Aminoisobutyric Acids; Antiviral Agents; Biological Availability; Clinical Trials as Topic; Coinfection; Drug Administration Schedule; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Leucine; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Thiazoles; Virus Replication | 2014 |
HCV F1/F2 patients: treat now or continue to wait.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Treatment Outcome; Uridine Monophosphate | 2014 |
Hepatitis C virus therapy in the direct acting antiviral era.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Sofosbuvir; Thiazoles; Uridine Monophosphate | 2014 |
Emerging therapeutic options in hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Oligopeptides; Proline; Quinolines; Simeprevir; Sulfonamides; Thiazoles; Treatment Outcome; Viral Load; Virus Replication | 2011 |
75 trial(s) available for leucine and Chronic Hepatitis C
| Article | Year |
|---|---|
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Death, Sudden; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Rwanda; Sofosbuvir; Sulfonamides; Treatment Failure | 2022 |
Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; COVID-19; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pandemics; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides | 2022 |
Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Area Under Curve; Benzimidazoles; Biological Availability; Body Weight; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Models, Biological; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Young Adult | 2020 |
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Young Adult | 2020 |
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2020 |
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Biopsy, Fine-Needle; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams, Macrocyclic; Leucine; Liver; Male; Middle Aged; Proline; Sulfonamides; Tissue Distribution; Young Adult | 2020 |
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Carbamates; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Leucine; Middle Aged; Proline; Pyrrolidines; Ritonavir; Russia; Sulfones; Treatment Outcome; Urea; Valine | 2019 |
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Asia; Benzimidazoles; Case-Control Studies; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Placebos; Prevalence; Proline; Pyrrolidines; Quinoxalines; Respiratory Tract Infections; Safety; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pilot Projects; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response | 2021 |
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Predictive Value of Tests; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Young Adult | 2017 |
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2017 |
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Methadone; Middle Aged; Naloxone; Opiate Substitution Treatment; Opioid-Related Disorders; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Surveys and Questionnaires; Young Adult | 2017 |
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2018 |
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Topics: Adult; Aged; Alanine Transaminase; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2018 |
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Placebos; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome | 2018 |
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; RNA, Viral; Sulfonamides; Viral Load | 2017 |
IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interleukins; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Recurrence; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2017 |
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoquinolines; Japan; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Viral Nonstructural Proteins | 2018 |
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2018 |
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome | 2018 |
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Topics: Adult; Aged; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Graft Rejection; Graft Survival; Hepatitis C, Chronic; Humans; Internationality; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver Transplantation; Male; Middle Aged; Prognosis; Proline; Pyrrolidines; Quinoxalines; Risk Assessment; Sulfonamides; Transplant Recipients; Treatment Outcome | 2018 |
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2018 |
Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Linear Models; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2018 |
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sulfonamides; Viral Load | 2018 |
Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
Topics: Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Recurrence; Retreatment; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.
Topics: Adult; Aged; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Drug Combinations; Fatigue; Female; Genotype; Headache; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
Topics: Aged; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Kidney; Lactams, Macrocyclic; Leucine; Male; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Glucose Intolerance; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Salvage Therapy; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Viremia | 2019 |
The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Severity of Illness Index; Sulfonamides; Sustained Virologic Response | 2019 |
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Liver Diseases; Male; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2019 |
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Pilot Projects; Proline; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult | 2013 |
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfones; Treatment Outcome; Urea; Viral Load | 2013 |
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load | 2013 |
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Peptide Hydrolases; Polyethylene Glycols; Proline; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viremia; Young Adult | 2013 |
Faldaprevir and deleobuvir for HCV genotype 1 infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Thiazoles; Viral Load | 2013 |
Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Asian People; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Time Factors; Treatment Outcome | 2014 |
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Placebos; Proline; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Topics: Adult; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Evolution, Molecular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sulfones; Urea; Viral Load; Viral Nonstructural Proteins | 2013 |
Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.
Topics: Acrylates; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Contraindications; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Virus Replication | 2014 |
Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.
Topics: Adult; Antiviral Agents; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Young Adult | 2015 |
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; RNA, Viral; Thiazoles; Treatment Outcome | 2015 |
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
Topics: Acrylates; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Female; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Quinolines; Ribavirin; Thiazoles; Young Adult | 2015 |
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles | 2015 |
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Leucine; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load; Viremia; Young Adult | 2015 |
Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Biopsy; Cyclopropanes; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Liver; Liver Cirrhosis; Male; Middle Aged; Proline; Sulfonamides | 2015 |
Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Resistance, Viral; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Mutation; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Japan; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sulfonamides; Treatment Outcome; Young Adult | 2016 |
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Placebos; Proline; Quinolines; Ribavirin; Salvage Therapy; Thiazoles; Treatment Outcome | 2016 |
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Microbial Sensitivity Tests; Middle Aged; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult | 2015 |
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Young Adult | 2016 |
GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Placebos; Proline; Quinoxalines; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2016 |
A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection.
Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-beta; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Sulfonamides | 2016 |
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
Topics: Acrylates; Adult; Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Leucine; Male; Middle Aged; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Quinolines; Ribavirin; RNA, Viral; Sustained Virologic Response; Thiazoles; Time Factors; Treatment Outcome; United States | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
Topics: Acrylates; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Prognosis; Proline; Quinolines; Ribavirin; RNA, Viral; Thiazoles; Viral Load; Young Adult | 2016 |
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Leucine; Liver Function Tests; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load; Young Adult | 2017 |
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inpatients; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Outpatients; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ritonavir; RNA, Viral; Sulfones; Urea; Young Adult | 2010 |
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Thiazoles; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2011 |
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sulfonamides; Young Adult | 2012 |
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Viral Nonstructural Proteins | 2013 |
92 other study(ies) available for leucine and Chronic Hepatitis C
| Article | Year |
|---|---|
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2021 |
Successful treatment of Japanese hemophilia patient co-infected with HIV and HCV genotype 4a by glecaprevir/pibrentasvir therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome | 2022 |
Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; China; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Male; Persistent Infection; Phylogeny; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2022 |
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2022 |
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome | 2022 |
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome | 2022 |
Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Patient Reported Outcome Measures; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Sulfonamides | 2022 |
Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides | 2022 |
Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Phylogeny; Proline; Pyrrolidines; Quinoxalines; Scotland; Substance Abuse, Intravenous; Sulfonamides | 2022 |
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Comorbidity; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Young Adult | 2019 |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Asia, Eastern; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Taiwan | 2020 |
A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2020 |
Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection.
Topics: Adolescent; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Hepatitis C and Compensated Cirrhosis Drug Approved for Eight-Week Treatment.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Approval; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; United States | 2020 |
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cohort Studies; Cyclopropanes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Multicenter Studies as Topic; Proline; Propensity Score; Pyrrolidines; Quinoxalines; Severity of Illness Index; Sulfonamides; Time Factors | 2020 |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Successful treatment with glecaprevir/pibrentasvir for chronic hepatitis C complicated by primary biliary cholangitis.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis, Biliary; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter?
Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter? Authors' reply.
Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Databases, Factual; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; United States | 2020 |
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2020 |
Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Heart Transplantation; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome; Viremia | 2020 |
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response | 2020 |
Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2021 |
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Republic of Korea; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency; Sulfonamides | 2020 |
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response | 2022 |
More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Peritoneal Dialysis; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Sulfonamides | 2020 |
Letter: now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority.
Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Letter: now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority-authors' reply.
Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2020 |
Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides | 2021 |
Hepatitis C and beta-thalassemia major in children: experience with glecaprevir/pibrentasvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Child; China; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Transplantation; Living Donors; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Tacrolimus; Uremia | 2021 |
Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland.
Topics: Adult; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Switzerland | 2021 |
Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results.
Topics: Adult; Age Distribution; Aged; Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Italy; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response | 2021 |
Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Registries; Sulfonamides; Sustained Virologic Response | 2021 |
Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Canada; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Registries; Salvage Therapy; Sofosbuvir; Sulfonamides | 2021 |
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2021 |
Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Registries; Sulfonamides; Sustained Virologic Response | 2021 |
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Medication Therapy Management; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2021 |
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides | 2022 |
Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Tacrolimus; Transplant Recipients | 2021 |
Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Area Under Curve; Asian People; Benzimidazoles; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Half-Life; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; White People | 2017 |
Mavyret and Vosevi--two new combinations for chronic HCV infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2017 |
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Placebos; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Surveys and Questionnaires; Sustained Virologic Response | 2018 |
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Self Report; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Beyond one virus: vaccination against hepatitis B after hepatitis C treatment.
Topics: Adult; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Expeditions; Genotype; Hepatitis B; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Vaccination | 2018 |
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Retreatment of hepatitis C virus: can it get any better?
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2018 |
Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
Topics: Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Failure; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Salvage Therapy; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Phylogeny; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Viral Nonstructural Proteins | 2018 |
Glecaprevir/Pibrentasvir (Mavyret) for the Treatment of Chronic Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2018 |
Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation.
Topics: Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Jaundice, Obstructive; Lactams, Macrocyclic; Leucine; Male; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency; Sulfonamides | 2019 |
Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Contraindications, Drug; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
Topics: Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Dialysis; Retreatment; Sulfonamides; Treatment Failure; Valine | 2019 |
NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Sequence Deletion; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2019 |
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sulfonamides; Viral Nonstructural Proteins | 2019 |
Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest?
Topics: Adult; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antidepressive Agents; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Mental Disorders; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Adherence and Compliance; Young Adult | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome | 2019 |
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Substance Abuse, Intravenous; Sulfonamides; Sustained Virologic Response; Young Adult | 2019 |
Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Leucine; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; Sulfonamides | 2019 |
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Markov Chains; Proline; Quinoxalines; Sofosbuvir; State Medicine; Sulfonamides; United Kingdom | 2019 |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Taiwan | 2019 |
Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Proline; Pyrrolidines; Quinoxalines; Recurrence; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome | 2019 |
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Monitoring; Drug Resistance, Viral; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Mutation; Oligopeptides; Polymorphism, Genetic; Proline; Protease Inhibitors; Quinolines; Thiazoles; Viral Nonstructural Proteins | 2014 |
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate | 2014 |
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; HIV Infections; Humans; Leucine; Male; Middle Aged; Oligopeptides; Patient Acceptance of Health Care; Proline; Prospective Studies; Protease Inhibitors; Quinolines; RNA, Viral; Switzerland; Thiazoles; Viral Load | 2015 |
[Vaniprevir with pegylated interferon and ribavirin in treatment for chronic hepatitis C].
Topics: Clinical Trials as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Indoles; Interferons; Isoindoles; Lactams, Macrocyclic; Leucine; Proline; Ribavirin; Sulfonamides | 2015 |
Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Topics: Acrylates; Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Leucine; Mutation; Oligopeptides; Polymorphism, Genetic; Proline; Protease Inhibitors; Quinolines; Thiazoles; Treatment Outcome; Viral Nonstructural Proteins | 2016 |
Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents.
Topics: Animals; Antiviral Agents; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Pan troglodytes; Proline; Protease Inhibitors; Sulfonamides; Treatment Outcome; Tubercidin; Viral Load; Viral Nonstructural Proteins | 2011 |
Amino acid substitutions in the hepatitis C virus core region are associated with postoperative recurrence and survival of patients with HCV genotype 1b-associated hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatectomy; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Leucine; Liver; Liver Function Tests; Liver Neoplasms; Male; Methionine; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Prognosis; RNA, Messenger; Survival Analysis; Viral Core Proteins | 2011 |
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.
Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Crystallography, X-Ray; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Kinetics; Leucine; Mutagenesis, Site-Directed; Mutation Rate; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Quinolines; Replicon; Thiazoles; Viral Nonstructural Proteins | 2012 |
Interferon-free treatment regimens for hepatitis C: are we there yet?
Topics: Aminoisobutyric Acids; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Oligopeptides; Proline; Quinolines; Ribavirin; RNA-Dependent RNA Polymerase; Thiazoles | 2011 |